AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(From Chemical Business NewsBase - Press Release)
Inflazyme Pharmaceuticals Ltd (Inflazyme) and Adprotech Ltd, have entered into an agreement whereby, subject to necessary regulatory approvals, Inflazyme will acquire Adprotech. Inflazyme will issue about 12.7 M common shares to acquire all outstanding Adprotech shares in a deal valued at about C$ 20 M. The acquisition will give Inflazyme a new inflammation technology platform, complement inhibition, and a potential novel clinical compound being developed for the treatment of rheumatoid arthritis. The acquisition of Adprotech will further strengthen Inflazyme's position as a leader in the development of novel anti-inflammatory therapies by adding a new, innovative, technology platform, complement inhibition, to its portfolio. Inflazyme will issue about 12.7 M common shares in exchange for all of the issued and outstanding ...